A brief Introduction of Beijing Sunho

Beijing Sunho Pharmaceutical Co., Ltd. was founded in 2000. By 2023, Sunho has assets of nearly 1.8 billion yuan and over 800 employees. Sunho has four R&D and production bases in Beijing, Zhongshan and Nanjing, and branches in the United States, Europe and Hong Kong, China. Sunho (stock code: 430017) is a national high-tech enterprise that undertakes many national technology and industrialization projects, and has obtained national project supports from the Ministry of Industry and Information Technology of the People’s Republic of China, the Ministry of Science and Technology of the People’s Republic of China, and the National Development and Reform Commission for many times. Among them, the industrialized CMC/CMO public service platform jointly built with the Shanghai Institute of Material Medical Chinese Academy of Sciences, has received special support for biomedical contract R&D and production service platform construction, marking the beginning of Sunho's entry into the national team of pharmaceutical industrialization services.

         Sunho focuses on providing validation batch and registration batch productions, global application and commercial production services for new and generic drugs, and is committed to providing the global pharmaceutical industry with customized R&D and production services required for the full life-cycle of drug products from early clinical research to marketing.

With the accumulation of drug R&D technology and industrialization experience, Sunho has formed a multi-core advantage represented by controlled release preparation technology, immediate release orally disintegrating tablet key technology and complex injection intelligent manufacturing technology. Currently, 8 workshops with cGMP production capacity have been built, containing 19 production lines, covering various dosage forms such as small-volume injections, freeze-dried powder for injection, conventional tablets, freeze-dried orally disintegrating tablets, and capsules. The workshop producing small-volume injections (terminal sterilization of vials and ampoules) has obtained the EMA certification (Germany and Poland), and the workshop producing small-volume injections and freeze-dried powder for injection (anti-tumor drugs) has submitted the application for the US FDA inspection. According to the principle of “Quality by Design”, Sunho has established a sound production quality assurance system by combining domestic and foreign regulations and guidelines such as the ICH, the US FDA, the EMA and the National Medical Products Administration, and built a complete information software management system, e.g., the LIMS system, IP-guard system, WMS system, BMS system, MES system, etc., forming a visualized closed-loop management from planning to compliant production, ensuring the data integrity and authenticity throughout the whole process.

In recent years, Sunho has provided CMC/CMO services for more than 100 pharmaceutical companies, including more than 40 new drugs. And nowadays, Sunho has become more thoughtful in its service concept, more professional in its service approaches, more efficient in service delivery and more comprehensive in its service value!

       With the corporate culture concept of “Self-surpassing and Co-Development”, driven by technological innovation and with the mission of promoting the evolution of China's new drug innovation and production services towards world-class standards, Sunho strives to become an excellent innovative international high-end pharmaceutical industry service provider by building and sharing a CMC/CMO international high-end service platform for China's new drug innovation and production, and deeply exploring multi-level and comprehensive one-stop cooperation such as Contract Research Organization (CRO) service and Marketing Authorization Holder (MAH) conversion service.